nach oben

Erschienen in:

07.07.2017 | Original Paper

CD163-positive cancer cells are potentially associated with high malignant potential in clear cell renal cell carcinoma

verfasst von: Chaoya Ma, Hasita Horlad, Koji Ohnishi, Takenobu Nakagawa, Sohsuke Yamada, Shohei Kitada, Takanobu Motoshima, Tomomi Kamba, Toshiyuki Nakayama, Naohiro Fujimoto, Motohiro Takeya, Yoshihiro Komohara

Erschienen in: Medical Molecular Morphology | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

CD163 is preferentially expressed by monocyte/macrophages; however, recent studies using immunohistochemistry (IHC) have reported that some cancer cells also express CD163. In the present IHC study, we investigated CD163 staining of cancer cells and macrophages in clear cell renal cell carcinoma (ccRCC) tissues and determined the relationship between cancer cell CD163 expression and clinical prognosis in patients with ccRCC. IHC for CD163 was performed in ccRCC tissues from 103 patients. CD163-positive cancer cells were detected in 35% of the patients (36/103); however, the positive signals on cancer cells were significantly lower than those on macrophages. CD163-positive cancer cells were preferentially detected in patients with high T classification, and females, and were significantly associated with shortened progression-free survival and a lower overall survival ratio. Notably, a high intensity of CD163-positive macrophage infiltration was detected in the CD163-positive cancer cell-high tumor areas. Although CD163 mRNA was detected in cultured macrophages, no CD163 mRNA was detected in two cultured RCC cell lines. The detailed mechanism by which a positive signal is detected on cancer cells has not been clarified. Detection of the CD163 antigen on cancer cells might be a useful marker for evaluating the clinical course of patients with ccRCC.

Motzer RJ, Bukowski RM (2006) Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 24:5601–5608CrossRefPubMed

Tanigawa G, Kawashima A, Yamaguchi S, Nishimura K, Miyoshi S, Kajikawa J, Meguro N, Yosioka T, Oka T, Hara T, Takayama H, Nonomura N, Osaka Renal Cell Carcinoma Clinical Study Collaboration (2011) Clinical outcome and prognostic factors of sorafenib in Japanese patients with advanced renal cell carcinoma in general clinical practice. Jpn J Clin Oncol 41:1265–1270CrossRefPubMed

Mikami S, Oya M, Mizuno R, Kosaka T, Ishida M, Kuroda N, Nagashima Y, Katsube K, Okada Y (2016) Recent advances in renal cell carcinoma from a pathological point of view. Pathol Int 66:481–490CrossRefPubMed

Nagashima Y, Kuroda N, Yao M (2013) Transition of organizational category on renal cancer. Jpn J Clin Oncol 43:233–242CrossRefPubMed

Fabriek BO, van Bruggen R, Deng DM, Ligtenberg AJ, Nazmi K, Schornagel K, Vloet RP, Dijkstra CD, van den Berg TK (2009) The macrophage scavenger receptor CD163 functions as an innate immune sensor for bacteria. Blood 113:887–892CrossRefPubMed

Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman HJ, Law SK, Moestrup SK (2001) Identification of the haemoglobin scavenger receptor. Nature 409:198–201CrossRefPubMed

Komohara Y, Ohnishi K, Kuratsu J, Takeya M (2008) Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J Pathol 216:15–24CrossRefPubMed

Takeya M, Komohara Y (2016) Role of tumor-associated macrophages in human malignancies: friend or foe? Pathol Int 66:491–505CrossRefPubMed

Komohara Y, Jinushi M, Takeya M (2014) Clinical significance of macrophage heterogeneity in human malignant tumors. Cancer Sci 105:1–8CrossRefPubMed

10.

Shabo I, Stål O, Olsson H, Doré S, Svanvik J (2008) Breast cancer expression of CD163, a macrophage scavenger receptor, is related to early distant recurrence and reduced patient survival. Int J Cancer 123:780–786CrossRefPubMed

11.

Maniecki MB, Etzerodt A, Ulhøi BP, Steiniche T, Borre M, Dyrskjøt L, Orntoft TF, Moestrup SK, Møller HJ (2012) Tumor-promoting macrophages induce the expression of the macrophage-specific receptor CD163 in malignant cells. Int J Cancer 131:2320–2331CrossRefPubMed

12.

Shabo I, Svanvik J (2011) Expression of macrophage antigens by tumor cells. Adv Exp Med Biol 714:141–150CrossRefPubMed

13.

Kanno H, Nishihara H, Wang L, Yuzawa S, Kobayashi H, Tsuda M, Kimura T, Tanino M, Terasaka S, Tanaka S (2013) Expression of CD163 prevents apoptosis through the production of granulocyte colony-stimulating factor in meningioma. Neuro Oncol 15:853–864CrossRefPubMedPubMedCentral

14.

Shabo I, Midtbö K, Andersson H, Åkerlund E, Olsson H, Wegman P, Gunnarsson C, Lindström A (2015) Macrophage traits in cancer cells are induced by macrophage-cancer cell fusion and cannot be explained by cellular interaction. BMC Cancer 15:922CrossRefPubMedPubMedCentral

15.

Shabo I, Olsson H, Elkarim R, Sun XF, Svanvik J (2014) Macrophage infiltration in tumor stroma is related to tumor cell expression of CD163 in colorectal cancer. Cancer Microenviron 7:61–69CrossRefPubMedPubMedCentral

16.

Kitada S, Yamada S, Kuma A, Ouchi S, Tasaki T, Nabeshima A, Noguchi H, Wang KY, Shimajiri S, Nakano R, Izumi H, Kohno K, Matsumoto T, Sasaguri Y (2013) Polypeptide N-acetylgalactosaminyl transferase 3 independently predicts high-grade tumours and poor prognosis in patients with renal cell carcinomas. Br J Cancer 109:472–481CrossRefPubMedPubMedCentral

17.

Ma C, Komohara Y, Ohnishi K, Shimoji T, Kuwahara N, Sakumura Y, Matsuishi K, Fujiwara Y, Motoshima T, Takahashi W, Yamada S, Kitada S, Fujimoto N, Nakayama T, Eto M, Takeya M (2016) Infiltration of tumor-associated macrophages is involved in CD44 expression in clear cell renal cell carcinoma. Cancer Sci 107:700–707CrossRefPubMedPubMedCentral

18.

Nakagawa T, Ohnishi K, Kosaki Y, Saito Y, Horlad H, Fujiwara Y, Takeya M, Komohara Y (2017) Optimum immunohistochemical procedures for analysis of macrophages in human and mouse formalin fixed paraffin-embedded tissue samples. J Clin Exp Hematop (in press)

19.

Horlad H, Ma C, Yano H, Pan C, Ohnishi K, Fujiwara Y, Endo S, Kikukawa Y, Okuno Y, Matsuoka M, Takeya M, Komohara Y (2016) An IL-27/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1/2) on infiltrating macrophages in lymphoma. Cancer Sci 107:1696–1704CrossRefPubMedPubMedCentral

20.

Komohara Y, Hasita H, Ohnishi K, Fujiwara Y, Suzu S, Eto M, Takeya M (2011) Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma. Cancer Sci 102:1424–1431CrossRefPubMed

21.

Komohara Y, Fujiwara Y, Ohnishi K, Takeya M (2016) Tumor-associated macrophages: potential therapeutic targets for anti-cancer therapy. Adv Drug Deliv Rev 99:180–185CrossRefPubMed

22.

Hasita H, Komohara Y, Okabe H, Masuda T, Ohnishi K, Lei XF, Beppu T, Baba H, Takeya M (2010) Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma. Cancer Sci 101:1913–1919CrossRefPubMed

23.

Chen EH, Olson EN (2005) Unveiling the mechanisms of cell-cell fusion. Science 308:369–373CrossRefPubMed

24.

Ding J, Jin W, Chen C, Shao Z, Wu J (2012) Tumor associated macrophage × cancer cell hybrids may acquire cancer stem cell properties in breast cancer. PLoS One 7:e41942CrossRefPubMedPubMedCentral

25.

Hintz KA, Rassias AJ, Wardwell K, Moss ML, Morganelli PM, Pioli PA, Givan AL, Wallace PK, Yeager MP, Guyre PM (2002) Endotoxin induces rapid metalloproteinase-mediated shedding followed by up-regulation of the monocyte hemoglobin scavenger receptor CD163. J Leukoc Biol 72:711–717PubMed

26.

Matsushita N, Kashiwagi M, Wait R, Nagayoshi R, Nakamura M, Matsuda T, Hogger P, Guyre PM, Nagase H, Matsuyama T (2002) Elevated levels of soluble CD163 in sera and fluids from rheumatoid arthritis patients and inhibition of the shedding of CD163 by TIMP-3. Clin Exp Immunol 130:156–161CrossRefPubMedPubMedCentral

27.

Weiss M, Schneider EM (2006) Soluble CD163: an age-dependent, anti-inflammatory biomarker predicting outcome in sepsis. Crit Care Med 34:2682–2683CrossRefPubMed

28.

Møller HJ, Moestrup SK, Weis N, Wejse C, Nielsen H, Pedersen SS, Attermann J, Nexø E, Kronborg G (2006) Macrophage serum markers in pneumococcal bacteremia: prediction of survival by soluble CD163. Crit Care Med 34:2561–2566CrossRefPubMed

29.

Reid M, Ma Y, Scherzer R, Price JC, French AL, Plankey MW, Grunfeld C, Tien PC (2017) Higher CD163 levels are associated with insulin resistance in hepatitis C virus-infected and HIV-infected adults. AIDS 31:385–393PubMedPubMedCentral

30.

Hassan WA, Baraka EA, Elnady BM, Gouda TM, Fouad N (2016) Serum Soluble CD163 and its association with various disease parameters in patients with systemic sclerosis. Eur J Rheumatol 3:95–100CrossRefPubMedPubMedCentral

31.

Enomoto Y, Suzuki Y, Hozumi H, Mori K, Kono M, Karayama M, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Inui N, Suzuki D, Ogawa N, Nakashima R, Mimori T, Iwashita T, Suda T (2017) Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease. Arthritis Res Ther 19:9CrossRefPubMedPubMedCentral

32.

Nederby L, Roug AS, Knudsen SS, Skovbo A, Kjeldsen E, Moller HJ, Hokland M (2015) Soluble CD163 as a prognostic biomarker in B-cell chronic lymphocytic leukemia. Leuk Lymphoma 56:3219–3221CrossRefPubMed

33.

Andersen MN, Abildgaard N, Maniecki MB, Møller HJ, Andersen NF (2014) Monocyte/macrophage-derived soluble CD163: a novel biomarker in multiple myeloma. Eur J Haematol 93:41–47CrossRefPubMed

34.

No JH, Moon JM, Kim K, Kim YB (2013) Prognostic significance of serum soluble CD163 level in patients with epithelial ovarian cancer. Gynecol Obstet Invest 75:263–267CrossRefPubMed

35.

Sugaya M, Miyagaki T, Ohmatsu H, Suga H, Kai H, Kamata M, Fujita H, Asano Y, Tada Y, Kadono T, Okochi H, Sato S (2012) Association of the numbers of CD163(+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma. J Dermatol Sci 68:45–51CrossRefPubMed

36.

Jensen TO, Schmidt H, Møller HJ, Høyer M, Maniecki MB, Sjoegren P, Christensen IJ, Steiniche T (2009) Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma. J Clin Oncol 27:3330–3337CrossRefPubMed

Titel: CD163-positive cancer cells are potentially associated with high malignant potential in clear cell renal cell carcinoma
verfasst von: Chaoya Ma
Hasita Horlad
Koji Ohnishi
Takenobu Nakagawa
Sohsuke Yamada
Shohei Kitada
Takanobu Motoshima
Tomomi Kamba
Toshiyuki Nakayama
Naohiro Fujimoto
Motohiro Takeya
Yoshihiro Komohara
Publikationsdatum: 07.07.2017
Verlag: Springer Japan
Erschienen in: Medical Molecular Morphology / Ausgabe 1/2018
Print ISSN: 1860-1480
Elektronische ISSN: 1860-1499
DOI: https://doi.org/10.1007/s00795-017-0165-8

Neu im Fachgebiet Pathologie

01.04.2024 | Forensische Traumatologie | CME

Springer Medizin

CD163-positive cancer cells are potentially associated with high malignant potential in clear cell renal cell carcinoma

Abstract

Neu im Fachgebiet Pathologie

Theoretische Grundlagen von Explosionen und Explosionsverletzungen

Auswirkungen vorgeschalteter Laborprozesse auf die Digitalisierung histologischer Schnittpräparate

Knochenmarkhistologie bei Zytopenien

Herausforderungen der Automation bei der quantitativen Auswertung von Leberbiopsien

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

The role of nanomaterials in cell delivery systems

Insulinoma-associated protein 1 (INSM1) is a useful marker for pancreatic neuroendocrine tumor

A comparative study between platelet-rich plasma and platelet-poor plasma effects on angiogenesis

Periodontal regeneration induced by porous alpha-tricalcium phosphate with immobilized basic fibroblast growth factor in a canine model of 2-wall periodontal defects

Correlation between immunohistochemical staining of CEACAM1 and clinicopathological findings in oral pre-neoplastic lesions and squamous cell carcinoma

Phenotypical change of tumor-associated macrophages in metastatic lesions of clear cell renal cell carcinoma

Neu im Fachgebiet Pathologie

Theoretische Grundlagen von Explosionen und Explosionsverletzungen

Auswirkungen vorgeschalteter Laborprozesse auf die Digitalisierung histologischer Schnittpräparate

Knochenmarkhistologie bei Zytopenien

Herausforderungen der Automation bei der quantitativen Auswertung von Leberbiopsien